## FORM 4

## **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

IIILO	שוור		IMIGE	COMMIS
Vachinaton	D C 2	0540		

OMB APPROVAL									
OMB Number:	3235-0287								

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See
Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

0.0.07 (1.1.1								
OMB Number:	3235-0287							
Estimated average burden								
hours per response:	0.5							

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person*  Bizily Scott  (Last) (First) (Middle)  C/O 4D MOLECULAR THERAPEUTICS, INC.  5858 HORTON STREET #455						Issuer Name and Ticker or Trading Symbol     AD Molecular Therapeutics, Inc. [FDMT]  3. Date of Earliest Transaction (Month/Day/Year) 08/19/2024														Owner (specify	
(Street)	VILLE C.	A	94608 (Zip)		4. If										Line)	ndividual or Joint/Group Filing (Check Applicable e)  Form filed by One Reporting Person  Form filed by More than One Reporting Person					
Table I - Non-Deriva  1. Title of Security (Instr. 3)  2. Transac Date (Month/Date)				action	ction 2A. Deemed Execution Date,			, 3 T C	ransact	ion	4. Securities Acquired (A) Disposed Of (D) (Instr. 3, 5)			5. Amor 4 and Securiti Benefic		nt of es ally Following	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership		
				0/202/	2024		$\perp$	Code \	/	Amount 500	(D)		rice \$6.49	Reported Transaction(s) (Instr. 3 and 4)		D		(Instr. 4)			
Common Stock         08/19/3           Common Stock         08/19/3										S <sup>(1)</sup>		500	_	-	\$15			D			
		Т	able II -										, or Ber ble sec			Owned					
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemd Execution if any (Month/Da	Date,	4. Transaction Code (Instr 8)		n of		6. Date Exercisal Expiration Date (Month/Day/Year			Amount of		of s ng e Secu		. Price of lerivative lecurity nstr. 5)	9. Number derivative Securities Beneficiali Owned Following Reported Transactio (Instr. 4)	ly	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
					Code	v	(A)	(D)	Date Exerc	cisable	Ex Da	piration ite	Title	Amo or Num of Shar	ber						
Stock Option (Right To Buy)	\$6.49	08/19/2024			M <sup>(1)</sup>			500		(2)	06	/17/2032	Common Stock	50	00	\$0	10,879		D		

## **Explanation of Responses:**

- $1.\ Transaction\ made\ pursuant\ to\ a\ 10b5-1\ trading\ plan\ adopted\ by\ the\ Reporting\ Person\ on\ October\ 10,\ 2023.$
- 2. The shares underlying the stock option award shall vest and become exercisable as to 1/48th of the underlying shares on each monthly anniversary of June 16, 2022 (the "Vesting Commencement Date") such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, while the grantee remains a service provider to the Company.

08/21/2024 By: /s/ Scott Bizily

\*\* Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.